查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1636752

膀胱癌治療和診斷市場預測至 2030 年：按癌症類型、治療、診斷、治療階段、最終用戶和地區進行的全球分析

Bladder Cancer Therapeutics and Diagnostics Market Forecasts to 2030 - Global Analysis by Cancer Type, Therapeutics, Diagnostics, Treatment Stage, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球膀胱癌治療和診斷市場預計在 2024 年達到 4.715 億美元，到 2030 年將達到 7.864 億美元，預測期內的複合年成長率為 8.9%。

膀胱癌治療和診斷是用於管理和識別膀胱癌的醫療治療和技術。治療可能包括多種治療方法，包括手術、化療、免疫療法、放射線治療和標靶治療，所有這些治療方法都是為了殺死癌細胞或阻止其生長。診斷包括多種測試和程序，例如尿液檢查、膀胱鏡檢查、影像（例如電腦斷層掃描、超音波）和切片檢查，以檢測和分期癌症。早期發現和先進治療對於提高存活率至關重要，個人化醫療的持續研究正在提高治療和診斷方法的有效性。

根據美國癌症協會統計，預計 2022 年美國將出現約 81,180 例膀胱癌新病例。

膀胱癌發生率上升

膀胱癌發生率的上升正在推動膀胱癌治療和診斷市場的發展。隨著越來越多的人被診斷出患有癌症，對先進診斷工具（如影像和生物標記測試）以及創新治療方案（如標靶治療、免疫療法和化療）的需求也日益成長。對早期發現和個人化治療的日益成長的需求推動了市場的成長，醫療保健提供者和製藥公司專注於開發新的治療方法和診斷解決方案，以應對膀胱癌日益成長的盛行率。

醫療費用高昂

膀胱癌的治療和診斷費用昂貴，這成為市場擴張的一大障礙，尤其是在中低收入國家。免疫療法和標靶治療等現代藥物價格昂貴，限制了患者的治療機會和負擔能力。保險覆蓋範圍和自付費用的差異加劇了這個問題，阻礙了快速診斷和有效治療，延遲了患者的治療效果並阻礙了更廣泛的市場應用。

早期檢測技術

早期檢測技術可實現早期診斷、改善治療效果並降低死亡率，對膀胱癌治療和診斷市場產生重大影響。液態切片等技術、診斷成像的進步以及生物標記測試使得人們能夠在早期階段識別癌症，從而製定個性化的治療方案。這將提高治療效率，最大限度地減少副作用並降低醫療成本。因此，在這些技術創新的推動下，膀胱癌診斷和治療市場正在迅速擴大。

治療的副作用

化療、免疫療法和放射線治療等膀胱癌治療的副作用會降低患者的依從性和治療效果，從而阻礙市場的成長。疲勞、噁心和免疫相關問題是一些可能降低生活品質並導致治療中斷或延遲的副作用。這將引起患者和醫療保健專業人士的擔憂，減緩某些治療方法的採用，並阻礙整個膀胱癌治療和診斷市場的成長。

COVID-19 的影響：

COVID-19 疫情導致選擇性手術延遲、患者就診減少、臨床試驗受限，擾亂了膀胱癌治療和診斷市場。診斷測試和治療的可用性受到影響，導致護理延遲。然而，疫情後對癌症治療的關注度增加以及遠端醫療和遠距離診斷的加速應用將支持市場復甦，從而長期推動對創新治療方法和診斷解決方案的需求。

膀胱鏡檢查細分市場預計將在預測期內成長至最大

膀胱鏡檢查預計將在預測期內佔據最大的佔有率，因為它可以直接觀察膀胱內壁，有助於識別腫瘤和異常。此診斷工具可支援切片檢查程序並有助於更精確的治療計劃。隨著全球膀胱癌發病率的不斷上升，膀胱鏡檢查在早期診斷和後續治療性介入中的作用正在推動診斷和治療領域的成長。

預計預測期內放射腫瘤學領域將以最高的複合年成長率成長。

放射治療領域預計在預測期內將以最高的複合年成長率成長，因為它通常與手術和化療結合以提高存活率。放射治療技術的進步，例如影像導航放射治療(IGRT) 和強度調控放射治療(IMRT)，提高了精確度並減少了副作用。這些技術創新以及對監測治療效果和檢測復發的先進診斷工具的日益成長的需求正在推動市場的發展。

佔比最大的地區：

由於膀胱癌盛行率上升、診斷工具不斷改進以及加護治療需求不斷成長，預計北美將在預測期內佔據最大的市場佔有率。人口老化和吸菸增多是導致癌症發生率上升的重要變數。此外，非侵入性診斷技術和免疫療法的進步、醫療保健和研究資金的增加正在推動該地區的市場擴張。

複合年成長率最高的地區：

由於癌症發病率上升、醫療保健意識增強、診斷技術的進步以及對標靶治療的需求不斷增加，預計亞太地區將在預測期內實現最高的複合年成長率。該地區醫療保健基礎設施的擴建和微創手術的採用也促進了市場的成長。此外，對新型生物標記和免疫療法的持續研究，以及獲得先進治療的機會的改善，也推動了亞太地區採用創新的膀胱癌診斷和治療方案。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的 SWOT 分析（最多 3 家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭性基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業進行基準化分析

目錄

第1章執行摘要

第 2 章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二手研究資料資訊來源
    • 先決條件

第3章 市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球膀胱癌治療與診斷市場（依癌症類型）

  • 膀胱移行細胞癌
  • 鱗狀細胞膀胱癌
  • 其他類型癌症

6. 全球膀胱癌治療與診斷市場（依治療方法）

  • 化療
  • 免疫療法
  • 標靶治療
  • 放射線治療
  • 外科手術
  • 其他療法

7. 全球膀胱癌治療與診斷市場（依診斷）

  • 膀胱鏡檢查
  • 膀胱超音波
  • 尿液檢查
  • 切片檢查
  • 血液檢查
  • 其他診斷

8. 全球膀胱癌治療與診斷市場（依治療階段）

  • 膀胱癌早期
  • 晚期膀胱癌

9. 全球膀胱癌治療和診斷市場（按最終用戶）

  • 醫院
  • 癌症研究所
  • 診斷實驗室
  • 門診手術中心
  • 其他最終用戶

第 10 章。

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Endo Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Hoffmann-La Roche AG
  • Johnson & Johnson
  • Kaiser Permanente
  • Merck & Co., Inc.
  • Novartis International AG
  • Pacific Edge Limited
  • Pfizer Inc.
  • Sanofi SA
Product Code: SMRC28393

According to Stratistics MRC, the Global Bladder Cancer Therapeutics and Diagnostics Market is accounted for $471.5 million in 2024 and is expected to reach $786.4 million by 2030 growing at a CAGR of 8.9% during the forecast period. Bladder cancer therapies and diagnostics are the medical treatments and technologies used to manage and identify bladder cancer. Therapeutics includes a range of treatments such as surgery, chemotherapy, immunotherapy, radiation therapy, and targeted therapy, aimed at killing cancer cells or preventing their growth. Diagnostics involve various tests and procedures, such as urine tests, cystoscopy, imaging (e.g., CT scans, ultrasounds), and biopsy, to detect and stage the cancer. Early detection and advanced treatments are crucial for improving survival rates, and ongoing research in personalized medicine is enhancing the effectiveness of both therapeutic and diagnostic approaches.

According to the American Cancer Society, in 2022, there are around 81,180 new cases of bladder cancer 61,700 in men and 19,480 in women in the United States.

Market Dynamics:

Driver:

Rising Incidence of Bladder Cancer

The rising incidence of bladder cancer is extensively driving the bladder cancer therapeutics and diagnostics market. As more individuals are diagnosed, there is increased demand for advanced diagnostic tools, such as imaging and biomarker testing, and innovative treatment options, including targeted therapies, immunotherapies, and chemotherapy. This growing need for early detection and personalized treatments is propelling market growth, with healthcare providers and pharmaceutical companies focusing on developing novel therapies and diagnostic solutions to address the rising prevalence of bladder cancer.

Restraint:

High Treatment Costs

The high expense of bladder cancer diagnostics and treatments is a significant barrier to market expansion, especially in low- and middle-income nations. Patient access and affordability are restricted by the high cost of modern medicines, such as immunotherapies and targeted treatments. This problem is made worse by gaps in insurance coverage and out-of-pocket costs, which obstruct prompt diagnosis and efficient treatment, delaying patient results and impeding wider market adoption.

Opportunity:

Early Detection Technologies

Early detection technologies are significantly impacting the bladder cancer therapeutics and diagnostics market by enabling earlier diagnosis, improving treatment outcomes, and reducing mortality rates. Technologies such as liquid biopsy, imaging advancements, and biomarker testing allow for the identification of cancer at its initial stages, leading to personalized treatment plans. This enhances the efficiency of therapies, minimizes side effects, and reduces healthcare costs. As a result, the market for bladder cancer diagnostics and treatments is expanding rapidly, driven by these innovations.

Threat:

Side Effects of Treatments

The adverse effects of bladder cancer therapies such as chemotherapy, immunotherapy, and radiation impede market growth by decreasing patient adherence and treatment efficacy. Fatigue, nausea, and immune-related problems are examples of adverse effects that might lower quality of life and cause therapy to be stopped or postponed. Patients and healthcare professionals become concerned about this, which slows the uptake of some treatments and hinders the market's overall growth for bladder cancer treatments and diagnostics.

Covid-19 Impact:

The COVID-19 pandemic disrupted the Bladder Cancer Therapeutics and Diagnostics Market by delaying elective surgeries, reducing patient visits, and limiting clinical trials. Diagnostic testing and treatment availability were impacted, leading to treatment postponements. However, the growing focus on cancer care post-pandemic, along with accelerated adoption of telemedicine and remote diagnostics has supported market recovery, driving demand for innovative therapies and diagnostic solutions in the long term.

The cystoscopy segment is expected to be the largest during the forecast period

The cystoscopy segment is expected to be the largest during the forecast period as it allows for direct visualization of the bladder lining, aiding in the identification of tumors or abnormalities. This diagnostic tool supports biopsy procedures, contributing to more precise treatment planning. As bladder cancer cases increase globally, cystoscopy's role in early-stage diagnosis and subsequent therapeutic interventions is driving growth in both the diagnostics and therapeutics sectors.

The radiotherapy segment is expected to have the highest CAGR during the forecast period

The radiotherapy segment is expected to have the highest CAGR during the forecast period because it is often combined with surgery or chemotherapy to improve survival rates. Advances in radiotherapy techniques, such as image-guided radiation therapy (IGRT) and intensity-modulated radiation therapy (IMRT), have enhanced precision, reducing side effects. These innovations are driving the market, along with the increasing demand for advanced diagnostic tools to monitor treatment efficacy and detect recurrence.

Region with largest share:

North America is anticipated to hold the largest market share during the forecast period because of the rising prevalence of bladder cancer, improvements in diagnostic tools, and the expanding need for focused treatments. The aging of the population and the increase in smoking are important variables that lead to increased cancer rates. Furthermore, advances in non-invasive diagnostic technologies and immunotherapies, as well as increased healthcare access and research funding, are driving market expansion in the area.

Region with highest CAGR:

Asia Pacific is anticipated to witness the highest CAGR over the forecast period owing to rising cancer incidences, increasing healthcare awareness, advancements in diagnostic technologies, and growing demand for targeted therapies. The region's expanding healthcare infrastructure and the adoption of minimally invasive procedures also contribute to market growth. Additionally, ongoing research into novel biomarkers and immunotherapies, along with enhanced access to advanced treatments, are boosting the adoption of innovative diagnostic and therapeutic solutions for bladder cancer in Asia-Pacific.

Key players in the market

Some of the key players in Bladder Cancer Therapeutics and Diagnostics market include Abbott Laboratories, AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Endo Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., GlaxoSmithKline PLC, Hoffmann-La Roche AG, Johnson & Johnson, Kaiser Permanente, Merck & Co., Inc., Novartis International AG, Pacific Edge Limited, Pfizer Inc. and Sanofi S.A.

Key Developments:

In September 2024, iCardio.ai announced collaboration with Abbott to develop AI applications for the medtech giant's imaging technologies.

In August 2024, Abbott announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading1 FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems.

In August 2024, The American Diabetes Association and Abbott recently announced a collaboration to better understand the nutritional needs of people living with diabetes, obesity, and metabolic dysfunction and how nutrition formulas can support those needs and overall health.

Cancer Types Covered:

  • Transitional Cell Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Other Cancer Types

Therapeutics Covered:

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Radiotherapy
  • Surgical Procedures
  • Other Therapeutics

Diagnostics Covered:

  • Cystoscopy
  • Bladder Ultrasound
  • Urinalysis
  • Biopsy
  • Blood Tests
  • Other Diagnostics

Treatment Stages Covered:

  • Early-Stage Bladder Cancer
  • Advanced-Stage Bladder Cancer

End Users Covered:

  • Hospitals
  • Cancer Research Institutes
  • Diagnostic Laboratories
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Bladder Cancer Therapeutics and Diagnostics Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Transitional Cell Bladder Cancer
  • 5.3 Squamous Cell Bladder Cancer
  • 5.4 Other Cancer Types

6 Global Bladder Cancer Therapeutics and Diagnostics Market, By Therapeutics

  • 6.1 Introduction
  • 6.2 Chemotherapy
  • 6.3 Immunotherapy
  • 6.4 Targeted Therapy
  • 6.5 Radiotherapy
  • 6.6 Surgical Procedures
  • 6.7 Other Therapeutics

7 Global Bladder Cancer Therapeutics and Diagnostics Market, By Diagnostics

  • 7.1 Introduction
  • 7.2 Cystoscopy
  • 7.3 Bladder Ultrasound
  • 7.4 Urinalysis
  • 7.5 Biopsy
  • 7.6 Blood Tests
  • 7.7 Other Diagnostics

8 Global Bladder Cancer Therapeutics and Diagnostics Market, By Treatment Stage

  • 8.1 Introduction
  • 8.2 Early-Stage Bladder Cancer
  • 8.3 Advanced-Stage Bladder Cancer

9 Global Bladder Cancer Therapeutics and Diagnostics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Cancer Research Institutes
  • 9.4 Diagnostic Laboratories
  • 9.5 Ambulatory Surgical Centers
  • 9.6 Other End Users

10 Global Bladder Cancer Therapeutics and Diagnostics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 AstraZeneca PLC
  • 12.3 Bristol-Myers Squibb Company
  • 12.4 Celgene Corporation
  • 12.5 Eli Lilly and Company
  • 12.6 Endo Pharmaceuticals Inc.
  • 12.7 F. Hoffmann-La Roche Ltd
  • 12.8 Genentech, Inc.
  • 12.9 GlaxoSmithKline PLC
  • 12.10 Hoffmann-La Roche AG
  • 12.11 Johnson & Johnson
  • 12.12 Kaiser Permanente
  • 12.13 Merck & Co., Inc.
  • 12.14 Novartis International AG
  • 12.15 Pacific Edge Limited
  • 12.16 Pfizer Inc.
  • 12.17 Sanofi S.A.

List of Tables

  • Table 1 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Cancer Type (2022-2030) ($MN)
  • Table 3 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Transitional Cell Bladder Cancer (2022-2030) ($MN)
  • Table 4 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Squamous Cell Bladder Cancer (2022-2030) ($MN)
  • Table 5 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Other Cancer Types (2022-2030) ($MN)
  • Table 6 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Therapeutics (2022-2030) ($MN)
  • Table 7 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 8 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 9 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Targeted Therapy (2022-2030) ($MN)
  • Table 10 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Radiotherapy (2022-2030) ($MN)
  • Table 11 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Surgical Procedures (2022-2030) ($MN)
  • Table 12 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Other Therapeutics (2022-2030) ($MN)
  • Table 13 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 14 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Cystoscopy (2022-2030) ($MN)
  • Table 15 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Bladder Ultrasound (2022-2030) ($MN)
  • Table 16 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Urinalysis (2022-2030) ($MN)
  • Table 17 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 18 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 19 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Other Diagnostics (2022-2030) ($MN)
  • Table 20 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Treatment Stage (2022-2030) ($MN)
  • Table 21 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Early-Stage Bladder Cancer (2022-2030) ($MN)
  • Table 22 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Advanced-Stage Bladder Cancer (2022-2030) ($MN)
  • Table 23 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By End User (2022-2030) ($MN)
  • Table 24 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 25 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Cancer Research Institutes (2022-2030) ($MN)
  • Table 26 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 27 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
  • Table 28 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.